Key Points

•Alzheimer's disease involves not just genetics, but also “epigenetic” changes that control how genes function.

•Serotonergic psychedelics like psilocybin and LSD are being studied for their ability to promote neuroplasticity and reduce neuroinflammation.

•Emerging research suggests psychedelics can modulate epigenetic mechanisms, potentially correcting the faulty gene expression seen in Alzheimer’s.

•These compounds may offer a new therapeutic approach by targeting the root biological processes of the disease.

•This research opens the door to a new paradigm in treating neurodegenerative disorders.Alzheimer’s disease is a specter that looms large in our society, a devastating illness that unravels memory, identity, and cognitive function. 

For decades, the scientific community has focused on the disease's hallmarks: the buildup of amyloid plaques and tau tangles in the brain. Yet, treatments targeting these proteins have yielded limited success, pushing researchers to look deeper. What if the key to unlocking Alzheimer’s lies not just in our fixed genetic code, but in the flexible “software” that runs it? This is the frontier of epigenetics, and it’s where the unlikely intersection of psychedelic science and neurodegeneration research is generating profound new hope.

This article will explore the revolutionary idea that serotonergic psychedelics—compounds like psilocybin and LSD—could offer a novel defense against Alzheimer’s disease by fundamentally altering how our genes are expressed. We will examine how the disease is driven by epigenetic dysregulation and how the neuroplastic and anti-inflammatory properties of psychedelics might counteract these harmful changes. This is not a simple story of a “magic bullet,” but a look at a potential paradigm shift in how we understand and treat this complex disease, moving from managing symptoms to possibly correcting the underlying biological symphony that has gone awry.

What is Epigenetics and How Does It Relate to Alzheimer's?

Epigenetics refers to modifications to your DNA that switch genes on or off without changing the DNA sequence itself. Think of it as the software that tells your genetic hardware what to do. In Alzheimer’s disease, epigenetic dysregulation is a key contributor, altering the expression of genes involved in inflammation, synaptic plasticity, and neuronal survival, thereby driving the disease’s progression (1, 2).

Our genes are not our destiny. Throughout our lives, environmental and lifestyle factors leave chemical marks on our DNA that influence which genes are active and which are silenced. In a healthy brain, this process is tightly regulated. However, in Alzheimer’s disease, this regulatory system goes haywire. Genes that should be quiet (like those promoting inflammation) are switched on, while genes that should be active (like those protecting neurons and supporting memory) are silenced. This epigenetic chaos contributes directly to the toxic environment in the brain where plaques and tangles form and neurons die. Understanding this process opens up a new therapeutic window: if we can correct these epigenetic errors, we might be able to slow or even halt the disease.

How Do Psychedelics Affect the Brain?

Serotonergic psychedelics, such as psilocybin and LSD, primarily act on the serotonin 2A (5-HT2A) receptor in the brain. Their activation of this receptor leads to profound changes in perception, cognition, and mood, but also triggers powerful biological effects, including the promotion of neuroplasticity—the growth of new neural connections—and the reduction of neuroinflammation, both of which are highly relevant to combating neurodegenerative diseases (3, 4).

Beyond the well-known subjective effects, these compounds are powerful agents of biological change. When they bind to the 5-HT2A receptor, they initiate a cascade of events inside the neuron that can lead to lasting structural and functional changes. Studies have shown that psychedelics can increase the density of dendritic spines—the small protrusions on neurons that receive signals from other cells—effectively helping the brain to form new connections and rewire itself. This is a crucial mechanism for learning and memory, and one that is severely impaired in Alzheimer’s disease. This is why psychedelic-assisted therapy is being explored for a variety of conditions.

Can Psychedelics Change Our Gene Expression?

Emerging preclinical evidence indicates that psychedelics can directly modulate epigenetic mechanisms, including histone modifications and DNA methylation. By influencing these processes, these compounds can induce sustained changes in gene transcription, potentially counteracting the harmful epigenetic landscape that contributes to Alzheimer’s pathology and promoting the expression of genes associated with neuroprotection and cognitive health (1, 5).

This is the crux of the new hypothesis. The very same mechanisms that allow psychedelics to promote neuroplasticity may also allow them to “rewrite” the faulty epigenetic code of Alzheimer’s. For example, studies suggest that psychedelics can influence enzymes that add or remove epigenetic marks on DNA and its associated proteins. By doing so, they could theoretically reactivate protective genes that have been silenced by the disease process or quiet the inflammatory genes that are running rampant. This is a far more fundamental intervention than simply clearing away plaques; it is an attempt to restore the brain’s own natural defense and repair mechanisms at a genetic level.

What Could This Mean for the Future of Alzheimer's Treatment?

The potential to use psychedelics as epigenetic modulators represents a paradigm shift in Alzheimer’s therapeutics. Instead of focusing solely on the downstream symptoms of the disease, this approach targets the upstream regulatory processes that drive it. This could lead to treatments that not only slow cognitive decline but also promote brain health and resilience, offering a more holistic and potentially more effective strategy (1, 4).

Imagine a treatment that doesn’t just manage the decline but actively works to restore healthy brain function from the inside out. This is the promise that psychedelic-based epigenetic therapies hold. While this research is still in its early stages and human clinical trials are needed, it offers a powerful new direction. It suggests a future where we might use carefully administered psychedelic compounds in a therapeutic setting to help the brain heal itself. To learn more, you can read our post on a related topic: A New Horizon for Mental Health in Aging: Could Psilocybin Help?

A New Chapter in Brain Health

The fight against Alzheimer’s disease requires bold new ideas. The discovery that psychedelics may be able to correct the epigenetic dysregulation at the heart of the disease is one of the most exciting developments in neuroscience today. It bridges the gap between mental health and neurodegeneration, showing that the same compounds that can heal the mind might also be able to heal the brain at a molecular level.

This research is a beacon of hope, illuminating a path toward a future where Alzheimer’s is not an inevitable decline but a treatable condition. As we continue to unravel the complex mysteries of the brain, it is clear that we must be open to exploring all potential avenues for healing, no matter how unconventional they may seem.

If you are interested in learning more about innovative approaches to mental and cognitive health, we invite you to contact us. Our practice is dedicated to providing compassionate, evidence-based care that honors the deep connection between mind and body.

Recommended Further Reading

•Unlocking Your Brain's Potential: Could Psychedelic Therapy Be the Future of Healthy Aging?

•Psychedelic Therapy (Service Page)

About the Author

This article was written by Jeff Jones, a Licensed Professional Counselor (LPC) in Texas in practice 27 years. He is a 2024 graduate of the CIIS Center for Psychedelic Therapies and Research program. With a compassionate and evidence-based approach, he helps clients navigate life’s challenges and find a path toward healing.

Disclaimer

The information in this article, including discussions of psychedelic-assisted psychotherapy, is for informational purposes only. Psychedelic-assisted psychotherapy has not been approved by all regulatory agencies in the United States, and its safety and efficacy are still being established. This content is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

(1) Gojani, E. G., Farzin, H., Sutherland, R. J., & Mohajerani, M. H. (2026). Serotonergic psychedelics as epigenetic modulators: A paradigm shift in Alzheimer's disease therapeutics. Neuroscience & Biobehavioral Reviews, 184, 106619. https://www.sciencedirect.com/science/article/abs/pii/S014976342600076X

(2) Androni, X., et al. (2025). Psychedelics meet human brain organoids: insights into Alzheimer's disease. Frontiers in Dementia. https://www.frontiersin.org/journals/dementia/articles/10.3389/frdem.2025.1605051/full

(3) Winkelman, M. J., Szabo, A., & Frecska, E. (2023). The potential of psychedelics for the treatment of Alzheimer's disease and related dementias. European Neuropsychopharmacology, 76, 3-16. https://www.sciencedirect.com/science/article/pii/S0924977X23001347

(4) Jones, S. A. V., & O'Kelly, A. (2020). Psychedelics as a Treatment for Alzheimer's Disease Dementia. Frontiers in Synaptic Neuroscience, 12, 34. https://pmc.ncbi.nlm.nih.gov/articles/PMC7472664/

(5) Haniff, Z. R., et al. (2024). Psilocybin for dementia prevention? The potential role of psilocybin in neurogenesis. Journal of Neurology, Neurosurgery & Psychiatry. https://pmc.ncbi.nlm.nih.gov/articles/PMC11847495/